Table 3 Risk factors for developing ILD

Age (years)

70 (57–79)^c

66 (37–79)^c

0.127^a

Gender (male/female)

5 / 5

66 / 29

0.287^b

GnP number of doses (time)

8 (3–28)^c

9 (2–63)^c

0.562^a

GnP administration period (days)

67 (16–289)^c

108 (7–931)^c

0.342^a

0.129^a

History of chemotherapy (+/−)

4 / 6

45 / 50

0.748^b

History of lung disease (+/−)

1 / 9

8 / 87

1.000^b

Lung metastasis (+/−)

1 / 9

11 / 84

1.000^b

Lung irradiation (+/−)

0 / 10

3 / 92

1.000^b

Smoker (+/−)

4 / 6

51 / 44

0.513^b

Heart disease (+/−)

2 / 8

18 / 77

1.000^b

Scr (mg/dL)

0.62 (0.47–0.61)^c

0.61 (0.33–1.38)^c

0.823^a

NSAIDs (+/−)

3 / 7

28 / 67

1.000^b

PPI (+/−)

9 / 1

71 / 24

0.445^b

Kampo medicines (+/−)

7 / 3

23 / 72

0.005^b

  Goshajinkigan (+/−)

7 / 3

16 / 79

0.001^b

Pregabalin (+/−)

2 / 8

6 / 89

0.168^b